Vera Therapeutics (NASDAQ:VERA) Upgraded at Wolfe Research

Vera Therapeutics (NASDAQ:VERA) was upgraded by investment analysts at Wolfe Research from a “peer perform” rating to an “outperform” rating in a research report issued to clients and investors on Wednesday,Benzinga reports. The firm currently has a $88.00 price target on the stock. Wolfe Research’s price objective suggests a potential upside of 118.63% from the company’s previous close.

Other equities analysts also recently issued reports about the company. TD Cowen reaffirmed a “buy” rating on shares of Vera Therapeutics in a research report on Friday, December 5th. JPMorgan Chase & Co. dropped their target price on Vera Therapeutics from $99.00 to $96.00 and set an “overweight” rating on the stock in a research note on Friday, December 19th. The Goldman Sachs Group upped their target price on Vera Therapeutics from $55.00 to $95.00 and gave the company a “buy” rating in a research report on Friday, December 19th. Pivotal Research set a $73.00 price target on Vera Therapeutics in a research note on Friday, December 5th. Finally, Wedbush raised their price target on Vera Therapeutics from $23.00 to $33.00 and gave the stock a “neutral” rating in a report on Thursday, December 11th. Ten investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, Vera Therapeutics currently has a consensus rating of “Moderate Buy” and an average target price of $81.45.

Vera Therapeutics Price Performance

VERA opened at $40.25 on Wednesday. The company has a market capitalization of $2.82 billion, a price-to-earnings ratio of -8.64 and a beta of 1.17. The company has a current ratio of 13.64, a quick ratio of 13.64 and a debt-to-equity ratio of 0.12. Vera Therapeutics has a 12-month low of $18.53 and a 12-month high of $56.05. The business’s fifty day simple moving average is $44.35 and its 200-day simple moving average is $36.55.

Vera Therapeutics (NASDAQ:VERA) last issued its quarterly earnings data on Thursday, February 26th. The company reported ($1.39) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.34) by ($0.05). During the same quarter in the prior year, the firm earned ($0.72) EPS. On average, equities research analysts anticipate that Vera Therapeutics will post -2.89 earnings per share for the current fiscal year.

Insider Activity at Vera Therapeutics

In other Vera Therapeutics news, Director Patrick G. Enright acquired 5,882 shares of the business’s stock in a transaction dated Thursday, December 11th. The shares were purchased at an average price of $42.50 per share, for a total transaction of $249,985.00. Following the completion of the purchase, the director directly owned 5,882 shares of the company’s stock, valued at $249,985. The trade was a ∞ increase in their ownership of the stock. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, CEO Marshall Fordyce sold 16,925 shares of the stock in a transaction on Monday, February 23rd. The stock was sold at an average price of $41.98, for a total transaction of $710,511.50. Following the completion of the sale, the chief executive officer owned 257,163 shares in the company, valued at $10,795,702.74. The trade was a 6.18% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold a total of 33,490 shares of company stock worth $1,405,910 in the last ninety days. 16.30% of the stock is owned by company insiders.

Institutional Investors Weigh In On Vera Therapeutics

Several hedge funds have recently added to or reduced their stakes in the business. Price T Rowe Associates Inc. MD grew its position in Vera Therapeutics by 49.0% during the 4th quarter. Price T Rowe Associates Inc. MD now owns 5,461,976 shares of the company’s stock worth $276,595,000 after purchasing an additional 1,795,537 shares during the period. Vestal Point Capital LP grew its holdings in Vera Therapeutics by 24.0% during the second quarter. Vestal Point Capital LP now owns 3,100,000 shares of the company’s stock worth $73,036,000 after acquiring an additional 600,000 shares during the period. Integral Health Asset Management LLC raised its position in Vera Therapeutics by 47.8% during the third quarter. Integral Health Asset Management LLC now owns 1,700,000 shares of the company’s stock valued at $49,402,000 after acquiring an additional 550,000 shares in the last quarter. Elmind Capital LP acquired a new position in Vera Therapeutics in the fourth quarter valued at approximately $24,434,000. Finally, Braidwell LP acquired a new position in Vera Therapeutics in the third quarter valued at approximately $13,738,000. 99.21% of the stock is owned by hedge funds and other institutional investors.

About Vera Therapeutics

Vera Therapeutics is a clinical-stage biotechnology company focused on developing novel immunotherapies that harness the body’s own regulatory T cells to treat autoimmune and inflammatory diseases. By leveraging a proprietary protein engineering platform, the company designs Treg-selective cytokine variants intended to restore immune balance and provide targeted, disease-modifying effects. Its pipeline comprises multiple preclinical and clinical candidates aimed at indications characterized by chronic inflammation and autoimmunity.

Founded in 2018 and headquartered in Cambridge, Massachusetts, Vera Therapeutics collaborates with leading academic and research institutions to advance its development programs.